Converting the Approved Semaglutide Schedule Into Marks on a U-100 Syringe

Semaglutide is one of the few compounds here with a dose set by a regulator rather than by a forum. The label gives you milligrams. A syringe reads in units. Converting between them is where the errors live.

This page takes the approved schedule as its anchor, converts every rung of it into volume and units, and sets out what the escalation costs in adverse events from the trials that measured them. Run your own figures through the semaglutide calculator as you go. Semaglutide sits in the weight loss and metabolic peptides category, and every worked example below is arithmetic on stated inputs rather than a recommendation to use any amount.

What is the approved semaglutide dosing schedule?

Semaglutide's approved schedule starts at 0.25 mg weekly and escalates over months to a standard weight-management dose of 2.4 mg weekly, with 7.2 mg approved in March 2026. Semaglutide is approved for chronic use, so this is maintenance therapy rather than a course, and weight regain after discontinuation is well documented. This is prescription medicine: which rung you are on, and when you move, belongs to your prescriber rather than to a chart.

One thing this page will not print is a week-by-week countdown between those rungs. The label states that escalation runs over months; the specific interval is a prescribing instruction, and inventing a number for it would be exactly the failure this site exists to correct. The strengths themselves are documented: 0.5 and 1.0 mg weekly were the doses in SUSTAIN-6 (n=3,297), and 1.7 or 2.4 mg were the maximum tolerated doses semaglutide was given at in SURMOUNT-5.

A related misreading is worth closing here. A "68-week protocol" is a trial duration, not a treatment plan — STEP 1 stopped at 68 weeks because that was its design. The evidence behind each of these amounts is set out in semaglutide: the nausea rate is 44.2%, not 73%, and the wider question of which compounds have a dose at all is in the peptide dosage guide.

How do you convert a semaglutide dose in milligrams to units?

Units on a U-100 syringe are volume markings, so one unit is 0.01 mL regardless of what is in the barrel. The conversion is a single expression: dose in milligrams, divided by concentration in mg/mL, multiplied by 100. At 5 mg/mL, a 2.4 mg dose is 0.48 mL, which is 48 units. The concentration term is the one people omit, and without it a units figure means nothing at all.

Worked example 1 — the standard maintenance dose

That is an example, not a recommendation, and it holds only for the two inputs at the top of it. Change the diluent volume and every row beneath moves. The same expression run at the starting dose gives 0.25 ÷ 5 × 100 = 5 units, which is a fifth of a tenth of a millilitre and sits low on any barrel you own.

The general form of this arithmetic, including the microgram conversions and the error classes it produces, is set out in how to calculate peptide doses. The semaglutide calculator performs the same operation and the reconstitution calculator handles the first two rows, but run it by hand once so you can tell when a tool has been handed the wrong input.

What does every rung of the ladder measure at three concentrations?

Concentration decides everything downstream, and the same milligram figure lands in three different places depending on a choice you made before mixing. At 5 mg/mL the approved ladder reads 5, 10, 20, 34, 48 and 144 units across its documented strengths. At half that concentration every figure doubles, and the top dose becomes physically impossible on a single barrel. At double it, the starting dose falls to two and a half units, where graduations stop being informative.

Read the table down a column rather than across a row and the design problem appears. No single concentration serves the whole ladder. A 2.5 mg/mL preparation reads the starting dose beautifully and cannot deliver the top one; a 10 mg/mL preparation holds the top dose comfortably and reduces the starting dose to a smear between marks. A concentration chosen for the first week of an escalation does not survive to the end of it.

That has a practical order of operations attached. The diluent volume is the only variable here you fully control, it is irreversible once added, and it should be chosen against the rung you are on rather than the rung you started at. The bacteriostatic water calculator works backwards from a target concentration to a volume, and the physical procedure is in reconstituting peptides step by step.

Why does the 7.2 mg dose break a 1 mL syringe?

At 5 mg/mL, 7.2 mg is 1.44 mL, or 144 units — more than a 1 mL barrel holds. The dose was approved in March 2026 on the strength of STEP UP, which randomised 1,407 participants and produced −20.7% at 72 weeks against −17.5% on 2.4 mg and −2.4% on placebo. The trial result is a human randomised finding; the syringe problem is arithmetic, and it is the newest reason the concentration decision cannot be made once and forgotten.

Worked example 2 — the same dose at a different concentration

The wrong response to the left-hand column is to split the dose across two draws and hope the total is right. The right response happens earlier, at the point the diluent goes in, and it is the reason this article puts concentration before conversion rather than after it. Where a vial is already mixed at a concentration that cannot deliver the intended amount, the honest position is that the arithmetic has run out of room, not that a careful hand can rescue it.

Run both columns through the semaglutide calculator and the reconstitution calculator before anything is mixed. Whether 7.2 mg is an appropriate amount for any individual is a prescriber's question and this page does not touch it.

How common is nausea on semaglutide, and where does 73% come from?

Semaglutide 2.4 mg produced nausea in 44.2% of STEP 1 participants against 17.4% on placebo, and the 73% figure that circulates online appears nowhere in that trial. Events were mostly mild to moderate and concentrated during dose escalation, and 4.5% of participants stopped treatment for gastrointestinal reasons. STEP 1 randomised 1,961 people and published its safety table, which makes the inflated number a sourcing failure rather than a disagreement about interpretation.

The shape of that profile matters more than the headline percentage, and it matters specifically to a titration page. A 44.2% incidence coexisting with a 4.5% discontinuation rate means most people who feel it keep going; the two numbers describe different things and quoting either alone misleads. For cross-compound context on how this class behaves, see the peptide side effects hub.

Why do the side effects cluster during escalation?

Nausea concentrates in the escalation window and fades with continued dosing, and the mechanism explains why. Friedrichsen et al., in Diabetes, Obesity and Metabolism in 2021, measured ad libitum energy intake 35% lower than placebo — 1,736 versus 2,676 kJ — with reduced hunger and increased satiety, and found no delayed gastric emptying at week 20. Slowed emptying is a real acute effect that attenuates; the appetite effect runs on hypothalamic and brainstem circuits and does not.

That distinction has a direct consequence for anyone reading a titration schedule. If the durable mechanism were mechanical, tolerance to the nausea would imply tolerance to the appetite effect, and each step up would trade one for the other. It does not, because the two run on different systems. The full mechanism is set out in semaglutide: the nausea rate is 44.2%, not 73%.

What follows from that is a statement about timing rather than about tolerability management, which is a clinical matter. The adverse events measured in STEP 1 were measured under a supervised escalation, in people whose vials contained a known quantity of drug, with a prescriber deciding when each step happened.

Which semaglutide risks are not dose-conversion problems?

Some of semaglutide's risks sit entirely outside the arithmetic, and no amount of careful measuring touches them. The boxed warning rests on rodent thyroid C-cell tumours — animal data, and it should be described as animal data. Semaglutide is contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2. Gallbladder events, recorded at 2.6% against 1.2% in STEP 1, are associated with rapid weight loss generally rather than with this molecule specifically.

• Personal or family history of medullary thyroid carcinoma, or MEN 2. A contraindication on the label, not a caution. This is a prescriber's determination before anything else happens.

• Severe, persistent abdominal pain. Pancreatitis has to be excluded. That is a clinical assessment, not something a dosing chart can help with.

• Gallbladder symptoms during rapid weight loss. Recorded at 2.6% against 1.2% on placebo in a 1,961-person trial, and associated with the rate of loss rather than the drug alone.

• The boxed warning itself. Rodent thyroid C-cell tumours — animal evidence. Describing it as a human observation overstates it; ignoring it understates a label warning.

• Anything that is not local, or not settling. A clinician, and not an article.

Every one of those routes to a doctor rather than to a calculator. Whether semaglutide is an appropriate treatment at all is a separate question from how to measure it, and it is answered by the evidence rather than by the arithmetic.

Which unit-conversion errors actually cause harm?

Three error classes account for most of the damage on this compound, and they are not equally visible. Units read as milligrams turns a volume marking into an amount of drug. A units figure quoted without a concentration is unusable, because the same mark delivers different amounts from different vials. The 100× step dropped turns 0.48 mL into a draw nobody can perform. FDA received "multiple reports of adverse events... that may be related to dosing errors associated with compounded injectable semaglutide products."

• "48 units" treated as a dose rather than a volume. A unit is 0.01 mL and nothing else. At 2.5 mg/mL the same 48 units delivers 1.2 mg, not 2.4 mg.

• A protocol quoting units with no concentration attached. It cannot be used, and it cannot be corrected. Ask for the vial size and the diluent volume, or discard the figure.

• The multiplication by 100 dropped. Millilitres and units differ by two decimal places, and the resulting draw is either physically impossible or a hundredth of the intention.

• Concentration changed mid-vial. Topping up an open vial with more diluent invalidates every unit figure calculated before it. Write the concentration and the date on the vial when you mix it.

• A 7.2 mg dose split across two draws without recording it. Two partial volumes are two chances to misread a barrel, and the total is unverifiable afterwards.

• A dose landing below roughly two units. Graduations stop being informative there. The fix is a different concentration, decided before mixing, not a steadier hand.

• Assuming the label milligram is a peptide milligram. That assumption is the subject of the next section, and it sits upstream of every figure on this page.

The technique errors that sit alongside these — reusing a transfer needle, injecting into a reactive site, recapping a sharp — are covered in how to inject peptides. As of 30 November 2024, FDA had received more than 392 adverse event reports for compounded semaglutide. Those are spontaneous reports rather than trial data.

Does the vial hold the milligrams the label claims?

Every figure above assumes the vial contains what the label says, and outside a pharmacy that assumption is the weakest link in the chain. Semaglutide's characteristic grey-market failure mode is underdosing rather than misidentification — a vial can be 99% pure and still hold substantially less peptide than claimed, because purity is a proportion and net content is a quantity. FDA states that semaglutide salt forms "are different active ingredients than are used in the approved drugs."

Worked example 3 — the same 48-unit draw from a vial that is not what it says

The 8.5 mg figure in that right-hand column is an illustration, not a measurement. We do not publish a fill-variance range for semaglutide, because this fact base does not carry one — unlike tirzepatide, where +2.6% to +26.7% is on record across 930 independent tests and is the whole subject of the tirzepatide dosing guide. Where a net-content figure exists for your batch, calculate from the assay rather than from the label.

The two mechanisms behind that column are separable and both are documented. Salt-form substitution changes what was weighed, covered in TFA vs acetate vs amidate peptide salt forms; fill shortfall changes how much of it is there, covered in why 10 mg isn't 10 mg. The reverse dose calculator runs the check backwards, from a draw you have already made to the amount it delivered.

Which semaglutide dosing claims survive the evidence?

Four of these nine claims hold. The label anchors the amounts, a U-100 unit is 0.01 mL by definition, STEP 1 reports 44.2% nausea and 7.2 mg exceeds a 1 mL barrel at 5 mg/mL. The rest fail in specific ways: a units figure without a concentration is meaningless, a trial duration is not a schedule, purity is not quantity, and the widely repeated 73% nausea rate does not appear in the trial it is attributed to.

Two rows there are worth carrying beyond this page. The nausea correction is the single most-copied error on this compound, and the monitoring point is a live one: from 1 January 2026 markers of semaglutide and tirzepatide are monitored both in and out of competition. Monitoring is not prohibition, but use is being tracked.

What do platform price data and independent testing show?

Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), and trust scores weight community reviews and independently verified HPLC purity equally at 50% each. Semaglutide price data shows 8 shops in stock, a median of $9.00/mg and a lowest tracked price of $3.00/mg on a 10 mg vial, across 20 comparable offers with per-vial prices from $29.99 to $300.00 (verified 10 August 2026).

Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Semaglutide's per-compound purity average and test count are read live from the Purity Index and the price page rather than printed here, because a figure we cannot date is worth less than a page you can refresh. Individual results with the testing laboratory named sit in the lab test database, and vendor-level detail on the semaglutide compound page.

Read the price spread as a risk signal rather than a bargain. Semaglutide has an approved version that exists on prescription, manufactured under pharmaceutical controls with a cold chain attached, and a per-milligram figure far below the rest of the market prices the absence of those things rather than discounting their presence. Vial size drives most of the visible spread, because packaging and testing costs are fixed regardless of fill — which is also why the cheapest per-milligram vial is often the one whose concentration suits the ladder least.

How do you check a semaglutide vial and your own arithmetic?

Six checks bracket everything on this page, and each resolves to a yes or a no. Mass spectrometry confirms identity at a mass near 4,113.6 Da; net peptide content confirms quantity; the salt form states what was weighed; the concentration written on the vial makes every later dose calculable; and running the conversion backwards catches transcription errors the forward calculation cannot see. A purity figure presented as if it were a quantity is the most common red flag on this compound.

The first three rows happen before the vial is yours; the last three happen in your kitchen. Neither set substitutes for the other, and the compound-specific vendor walkthrough is in where to buy semaglutide. Anything about whether semaglutide is appropriate for you, at any amount, is a clinician's question.

The trial that would settle this

The amounts on this page are settled and the conversion is not. Semaglutide's efficacy is established across STEP 1 (n=1,961), STEP 5 (n=304) and SELECT (n=17,604), and its adverse-event profile is published to a decimal place — but every one of those figures was generated with a supervised dose from a known-quantity vial. What has never been measured is the accuracy of the conversion step performed at home, which is the step FDA's adverse-event reports point at.

Frequently Asked Questions

How many units is 2.4 mg of semaglutide?

It depends entirely on the concentration, which is why the question cannot be answered without one. At 5 mg/mL, 2.4 mg is 0.48 mL, which is 48 units on a U-100 syringe. At 2.5 mg/mL the same dose is 96 units, and at 10 mg/mL it is 24 units. Any units figure quoted without a concentration is unusable.

How much bacteriostatic water should go into a semaglutide vial?

There is no standard volume, and unless a label states one the choice is yours rather than the manufacturer's. Choose it against the rung of the ladder you are actually on, because no single concentration serves both a 0.25 mg starting dose and a 7.2 mg high dose on the same barrel. The bacteriostatic water calculator works backwards from a target concentration.

Is semaglutide's nausea rate really 73%?

No. STEP 1 reported nausea in 44.2% of participants on 2.4 mg against 17.4% on placebo, with events mostly mild to moderate and concentrated during escalation. Fewer than five percent — 4.5% — discontinued for gastrointestinal reasons. The 73% figure appears nowhere in the trial it is usually attributed to.

What if a dose works out to less than one unit?

Change the concentration rather than estimating between graduations. Below roughly two units the marks stop being informative, and the fix is upstream: reconstituting with more diluent lowers the concentration and raises the number of units for the same amount. That decision has to be made before the diluent goes in, because it cannot be undone afterwards.

Does the 7.2 mg dose fit in a single injection?

Not at 5 mg/mL, where it works out to 1.44 mL or 144 units against a 100-unit barrel. At 10 mg/mL the same dose is 0.72 mL, or 72 units, which does fit. The dose was approved in March 2026 on STEP UP, which produced 20.7% mean weight loss at 72 weeks in 1,407 participants.

Can you still get compounded semaglutide?

Largely no. FDA declared the injection shortage resolved on 21 February 2025, and enforcement discretion ended on 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities. What survives is narrow and patient-specific, and the access picture is set out in can you get semaglutide without a prescription.

Where the chart ends and the prescription begins

This page converts an approved schedule into syringe readings, and that is the whole of what it does. It does not decide which rung anyone should be on, when to move between them, or whether semaglutide is the right compound at all — those are prescriber decisions, and the trials that produced every number here were run with a prescriber attached. Getting the conversion right on a dose nobody chose for you is a precisely measured guess.

The two halves of this article fail differently, which is worth carrying away. The arithmetic is deterministic: 2.4 mg at 5 mg/mL is 48 units, and it will be 48 units tomorrow. The inputs are not deterministic at all — a label milligram is an assumption about a vial, a units figure without a concentration is noise, and the adverse-event profile that makes escalation tolerable was measured under conditions a research vial does not reproduce. For sub-therapeutic practice and what the evidence supports, see GLP-1 microdosing.

Browse the weight loss and metabolic peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the semaglutide calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.